NCT03460678 2020-03-05
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
Hikma Pharmaceuticals LLC
Phase 4 Terminated
Clinical Trials
10 trialsNCT04145570 2019-10-30
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Quadras Scientific Solutions
Phase 4 Completed
NCT00642733 2016-08-24
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 4 Terminated
NCT01066884 2016-08-24
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01320501 2016-05-13
REALME
National Guard Health Affairs
Phase 4 Suspended
NCT02031601 2016-03-29
TCL-1
Qilu Hospital of Shandong University
Phase 4 Unknown
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT01196078 2015-07-27
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01230710 2015-03-30
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
Hoffmann-La Roche
Phase 4 Completed
NCT02399566 2015-03-26
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Hunan Province Tumor Hospital
Phase 4 Unknown